Vyleesi Older Adult (50 to 64) Dosing: What Clinicians and Patients Need to Know

What Is the Standard Bremelanotide Dose for Women Aged 50 to 64?

The approved dose of bremelanotide is 1.75 mg delivered as a single subcutaneous injection approximately 45 minutes before sexual activity. The FDA label does not specify a lower starting dose for adults aged 50 to 64, and pharmacokinetic data from the RECONNECT program did not identify age-driven exposure differences significant enough to mandate adjustment in this bracket. Clinicians still need to weigh individual risk factors, nausea tolerance, cardiovascular profile, and concurrent medications, before the first injection.

How the Dose Is Administered

Bremelanotide comes as a prefilled, single-use autoinjector delivering 1.75 mg in 0.4 mL. Patients inject into the abdomen or thigh (not a vein or muscle). The FDA prescribing information specifies that patients should not take a second dose within 24 hours, regardless of effect. Rotating injection sites reduces local skin reactions, which occurred in roughly 13% of trial participants.

Why No Formal Dose Reduction for Ages 50 to 64?

Population pharmacokinetic modeling submitted to the FDA showed that age, within the studied range, did not meaningfully alter bremelanotide area under the curve or peak concentration [1]. Hepatic and renal function, not chronological age alone, drive clinically meaningful pharmacokinetic variation. Women aged 50 to 64 with normal hepatic and renal function receive the same 1.75 mg dose as younger adults. The FDA label does caution against use in severe hepatic impairment (Child-Pugh C), a consideration more prevalent as patients age [2].

Understanding HSDD and Why Age 50 to 64 Is a Distinct Clinical Window

Hypoactive sexual desire disorder is defined as persistently low sexual desire causing marked distress. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Society for the Study of Women's Sexual Health (ISSWSH) both recognize HSDD as a diagnosable, treatable condition [3]. For women aged 50 to 64, the biology of desire is complicated by the perimenopausal transition, a phase characterized by erratic estradiol fluctuation, rising FSH, and vasomotor symptoms that themselves suppress libido.

Perimenopause Overlap With HSDD

Perimenopause typically begins in the mid-40s and extends until 12 months after the final menstrual period, which in the United States occurs at a median age of 51.4 years [4]. A woman presenting at age 53 with low desire may be experiencing HSDD driven by melanocortin pathway dysfunction, estrogen withdrawal, psychosocial stressors, or all three simultaneously. Bremelanotide targets melanocortin-4 receptors centrally, a mechanism distinct from hormone replacement, making it theoretically additive rather than redundant with concurrent HRT.

The RECONNECT Trial Data

The RECONNECT program comprised two Phase 3 randomized controlled trials (N=1,267 combined) published in Obstetrics and Gynecology in 2019 [5]. Premenopausal women with HSDD who received bremelanotide 1.75 mg as-needed showed statistically significant improvements on the Female Sexual Function Index desire domain and on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score compared with placebo (P<0.001 for both co-primary endpoints). The responder rate, defined as a clinically meaningful improvement on both co-primaries, was 25.0% for bremelanotide vs. 17.0% for placebo. Women aged 50 to 64 were underrepresented in RECONNECT because the label targets premenopausal women, a limitation discussed in the 2019 publication itself [5].

Cardiovascular Considerations in the 50 to 64 Age Group

Cardiovascular disease risk rises sharply after age 50 in women, driven by estrogen decline. The FDA prescribing label for bremelanotide carries a warning that the drug transiently increases blood pressure and decreases heart rate, and should not be used in women with cardiovascular disease or high cardiovascular risk [2]. This warning carries direct clinical weight for the 50 to 64 bracket.

The Transient Hemodynamic Effect

In clinical pharmacology studies, bremelanotide produced a mean maximum increase in systolic blood pressure of approximately 6 mmHg and a mean maximum decrease in heart rate of approximately 4 beats per minute. These changes peak around 4 hours post-dose and resolve within 12 hours [2]. For a 55-year-old woman with well-controlled stage 1 hypertension (systolic 135 mmHg at rest), that 6 mmHg rise is unlikely to be dangerous but should be documented and monitored.

Screening Before Prescribing in This Age Group

The American Heart Association's 2022 Guideline on Cardiovascular Risk Assessment recommends 10-year ASCVD risk calculation for all adults beginning at age 40 [6]. A 10-year ASCVD risk at or above 10% places a woman in the intermediate-to-high category where bremelanotide's transient pressor effect warrants a formal benefit-risk conversation. Clinicians should also review whether the patient is taking antihypertensive agents, since a hemodynamic spike from bremelanotide could transiently override dose-adjusted medications taken earlier that day.

When to Avoid Bremelanotide Outright

Women with known coronary artery disease, heart failure, or a recent myocardial infarction should not receive bremelanotide. The Endocrine Society's clinical practice guidelines on female sexual dysfunction recommend thorough cardiovascular screening before any pharmacological intervention for desire disorders in midlife women [7]. A resting ECG is not required by the label, but many practitioners obtain one in women over 50 with cardiovascular risk factors.

Polypharmacy: The Critical Concern for Ages 50 to 64

Adults aged 50 to 64 use an average of 4.5 prescription medications, a figure that has increased steadily over the past two decades according to CDC data [8]. Bremelanotide has documented interactions that become more likely as the number of concurrent medications increases.

Naltrexone and Indomethacin Interactions

The FDA label states that bremelanotide may reduce systemic exposure to co-administered drugs, specifically naltrexone and indomethacin, by approximately 35% and 50%, respectively [2]. This interaction is mediated through delayed gastric emptying caused by bremelanotide-induced nausea, not through cytochrome P450 pathways. A woman using low-dose naltrexone for pain or mood management should time doses to avoid within at least 2 hours of bremelanotide administration.

Serotonergic Medications

Women aged 50 to 64 carry a high prevalence of SSRI and SNRI use, often prescribed for vasomotor symptoms as well as depression. SSRIs themselves lower desire as a side effect [9]. Combining an SSRI with bremelanotide does not create a pharmacodynamic serotonin syndrome risk because bremelanotide does not act on serotonin receptors, but prescribers should recognize that the SSRI may blunt bremelanotide's clinical benefit by independently suppressing desire.

Opioid Analgesics

Opioids reduce gonadotropin-releasing hormone pulsatility, lowering testosterone and estradiol levels, a contributor to HSDD in chronic pain patients [10]. The nausea profile of bremelanotide (40% incidence) may compound opioid-related nausea, making combined use uncomfortable for patients. Clinicians should discuss this additive risk explicitly.

Nausea Management: Practical Steps for Older Adults

Nausea is the most common adverse effect of bremelanotide. In RECONNECT, 40.0% of bremelanotide recipients reported nausea versus 1.4% of placebo recipients [5]. Older adults may tolerate nausea less well than younger patients, particularly those with existing gastroesophageal reflux or gastroparesis.

Pre-Treatment Strategies

The FDA label permits, and the prescribing information discusses, prophylactic antiemetic use before bremelanotide injection [2]. Ondansetron 4 mg taken 30 minutes before the injection is a common clinical approach, though this adds a drug to a patient's regimen. Patients should avoid large fatty meals within 2 hours of dosing, since high-fat food slows gastric emptying and extends the nausea window.

Dose Timing Adjustment

Some clinicians advise patients to experiment with injecting 60 to 90 minutes before activity rather than the labeled 45 minutes, allowing the peak nausea (which occurs around 30 to 60 minutes post-injection) to subside before intimacy begins. This is not a labeled recommendation but reflects real-world clinical practice.

Skin and Injection Site Reactions in Older Adults

Bremelanotide produces focal hyperpigmentation, darkening of the face, gums, or breasts, in a subset of users. In clinical trials, this occurred in approximately 1% of users with prolonged use (more than 8 doses per month) [2]. Older women with existing pigmentation changes from sun exposure or melasma may find additional hyperpigmentation more noticeable. Hyperpigmentation was generally reversible after discontinuation in trial participants, though resolution took several months in some cases.

Injection site bruising and hematoma are more likely in patients taking anticoagulants or antiplatelet therapy. Women aged 50 to 64 on low-dose aspirin for cardiovascular prevention should apply gentle pressure after injection and rotate sites consistently.

Off-Label Use in Perimenopausal Women: What the Evidence Says

The FDA approved bremelanotide specifically for premenopausal women. Perimenopause straddles this boundary, some perimenopausal women still have regular or near-regular cycles and technically remain "premenopausal," while others have transitioned to irregular cycles and lower endogenous estrogen. The ISSWSH 2022 Position Statement on Female Sexual Dysfunction acknowledges that desire disorders in perimenopausal and postmenopausal women share overlapping biology with HSDD in premenopausal women, but notes that controlled trial data for bremelanotide in postmenopausal patients is limited [3].

A woman aged 58 who had her last menstrual period 18 months ago is postmenopausal and outside the approved label. Her prescribing clinician would be using bremelanotide off-label, which is legal but requires thorough documentation of the rationale and informed consent discussion.

The HealthRX clinical team uses the following decision framework for women aged 50 to 64 requesting bremelanotide:

1. Confirm premenopausal or early perimenopausal status (FSH <40 mIU/mL, menstrual irregularity present but not cessation for 12 months).
2. Calculate 10-year ASCVD risk. If risk is at or above 10%, conduct cardiovascular benefit-risk counseling before prescribing.
3. Review all concurrent medications for naltrexone, indomethacin, and opioid overlap.
4. Screen for nausea-prone conditions (GERD, gastroparesis, concurrent opioid use).
5. Discuss realistic expectations: 25% of bremelanotide users in RECONNECT met both co-primary endpoints vs. 17% on placebo, a real but modest effect size [5].
6. If postmenopausal (12-plus months since last period), document off-label discussion and consider whether concurrent genitourinary syndrome of menopause treatment is needed first.

Dosing Across Renal and Hepatic Function: What Changes at 50 to 64?

Kidney function declines roughly 1 mL/min per year after age 40 [11]. A 60-year-old woman with a creatinine clearance between 30 to 59 mL/min (Stage 3 chronic kidney disease) has no formal dose adjustment required by the FDA label, but reduced renal clearance modestly increases bremelanotide exposure [2]. The prescribing information states that severe renal impairment (creatinine clearance <30 mL/min) has not been formally studied, so use in that population requires caution.

Hepatic metabolism via multiple CYP pathways and direct peptide hydrolysis drives bremelanotide clearance. Mild to moderate hepatic impairment (Child-Pugh A or B) does not require dose reduction. Severe hepatic impairment (Child-Pugh C) is listed as a contraindication in the prescribing label [2]. Clinicians treating women aged 50 to 64 with NAFLD-related hepatic fibrosis should assess Child-Pugh scoring before prescribing.

Comparing Bremelanotide With Flibanserin in the 50 to 64 Age Group

Flibanserin (Addyi) is the only other FDA-approved pharmacotherapy for HSDD in premenopausal women. A direct comparison is useful for clinicians managing older adults in this age range.

Flibanserin requires daily dosing at bedtime (100 mg oral tablet), carries a boxed warning for hypotension and syncope when combined with alcohol, and has a mandatory REMS program [12]. Bremelanotide is taken as-needed, requires no REMS, and has no alcohol interaction warning, making it operationally simpler for women who do not want a daily regimen.

In the VIOLET study and the SNOWDROP trial, flibanserin at 100 mg nightly produced mean improvements in satisfying sexual events and desire scores that were statistically significant but similarly modest in absolute terms, roughly one additional satisfying sexual event per month [13]. Neither drug has been tested head-to-head.

For a 52-year-old woman with irregular periods who wants on-demand treatment rather than a daily pill, bremelanotide's as-needed profile is often preferable, provided cardiovascular screening passes.

Patient Counseling Points for the 50 to 64 Age Group

Clear, direct counseling improves adherence and safety. The following points address the specific concerns of patients in this age bracket.

Expectation Setting

Bremelanotide does not work like a stimulant. It does not produce immediate arousal. Patients should be told that it modulates melanocortin receptors to lower the threshold for desire, and that the drug's effect may be subtle, fewer days of absent desire rather than a dramatic surge. The RECONNECT responder rate of 25% versus 17% for placebo [5] reflects a real clinical signal, but about 75% of users do not meet the stringent dual-endpoint responder definition.

Blood Pressure Awareness

Patients should be asked to check their blood pressure the first time they use bremelanotide, approximately 4 hours after injection, to document their personal hemodynamic response. Women with home BP monitors, common in the 50 to 64 bracket given hypertension prevalence, can do this easily.

Skin Changes

Patients should examine their face, gums, and breast skin after each injection cycle. Any new darkening should be reported promptly. If focal hyperpigmentation appears, the prescribing clinician may recommend reducing injection frequency or discontinuing.

Storage

Bremelanotide autoinjectors should be stored at room temperature, between 68°F and 77°F (20°C and 25°C), and kept away from light and heat [2]. Patients who travel frequently should be counseled that leaving autoinjectors in a hot car may degrade the peptide.